What BresMed does

BresMed is a private, for-profit health economics and outcomes research (HEOR) consultancy headquartered in Sheffield, United Kingdom, founded in 2006. The firm operates with 51-100 employees, positioning it as a specialized boutique within the UK life sciences advisory market. BresMed delivers health economic solutions focused on evidence generation, economic modeling, and value demonstration to support pharmaceutical and biotech clients across market access, reimbursement, and HTA submission workflows. The firm operates within a broader healthcare consulting ecosystem — integrated with Lumanity, a 1,200-person global life sciences value demonstration platform headquartered in Morristown, NJ (North America) and London (Europe) serving 150+ pharmaceutical and 100+ biotech companies across 50+ countries. Post-integration, BresMed retains its distinct brand identity while functioning as the group's UK-centered HEOR capability, contributing to a broader service portfolio spanning commercialization, clinical and regulatory, medical affairs, real-world evidence, patient-centered outcomes, market access, and brand communications.

BresMed's narrow HEOR focus — distinct from full-service management consultancies — reflects a niche positioning targeting clients needing rigorous cost-effectiveness analysis, budget impact models, global value dossiers, and payer-facing evidence packages for HTA bodies such as NICE, SMC, and other European reimbursement authorities. As a UK-based specialist founded nearly two decades ago, the firm has accumulated methodological credibility and long-standing client relationships in a discipline where domain expertise and peer-reviewed track record are decisive procurement criteria.

The firm's combined service offering spans strategy, evidence, and engagement capabilities, increasingly augmented by proprietary technology platforms including EMULaiTOR (AI-powered synthetic personas), ONEE (omnichannel engagement), Pathway (patient journey mapping), Expert Navigator (KOL management), Ignite (launch excellence), WeConvEEn (HCP/HCO/patient engagement), and Engage (HCP insights). Group-level ISO 42001 certification for responsible AI, achieved in 2024, signals investment in AI-augmented evidence-generation workflows. The business model is professional services / consulting — quote-based, customized engagements sold primarily through direct enterprise field sales to pharmaceutical and biotech decision-makers.

Name

BresMed

Legal name

Lumanity Inc.

Website

https://bresmed.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

BresMed is a Sheffield, UK-based health economics and outcomes research consultancy founded in 2006, employing 51-100 staff to deliver health economic solutions for pharmaceutical and biotech clients, now operating as part of the Lumanity life sciences value demonstration platform.

Ownership category

akta.pro rank

Headquarters

HQ city

Sheffield

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Consulting and Advisory Services: Professional consulting services spanning strategic planning, evidence generation, and stakeholder engagement across the product lifecycle. Services cover commercialization, market access, HEOR, clinical and regulatory expertise, medical affairs, and patient-centered outcomes research.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

BresMed is a health economic and outcomes research consultancy that delivers health economic solutions to pharmaceutical and biotech clients. The firm provides specialist services in HEOR, real-world evidence, patient-centered outcomes, market access, clinical and regulatory support, and medical affairs engagement across the medicine development lifecycle. BresMed operates with 51-100 employees from its Sheffield, UK headquarters and is positioned within the Lumanity life sciences value demonstration partnership.

Product overview

Lumanity offers a platform-plus-modules architecture combining tech-enabled services with AI-based tools. The product portfolio includes Ignite (launch excellence platform), EMULaiTOR (AI-powered synthetic personas), Expert Navigator (thought leader engagement optimization), Pathway (patient journey mapping), ONEE (omnichannel customer journeys), WeConvEEn (HCP/HCO/patient engagement), and Engage (HCP insight reporting). These products are designed to work together to provide end-to-end commercialization support across the medicine development lifecycle.

Differentiator

Problem solved

Functional benefit

Brands

• Leith: A Lumanity business specializing in creative agency services, including patient and HCP communications campaigns. Won Grand Clio Award 2022 for CPR awareness creative.

Products and services

• Health Economics and Outcomes Research (HEOR) HEOR consulting services that help pharmaceutical and biotech clients navigate market access with comprehensive health economics and outcomes research, designed for evidence generation and reimbursement support.
• Real-World Evidence Real-world evidence generation service that leverages real-world data to produce evidence meeting the needs of regulatory, payer, and clinical stakeholders for pharmaceutical and biotech clients.
• Patient-Centered Outcomes Research Patient-focused outcomes research service that enhances clinical trials with patient-centered outcome measures for impactful treatments, targeting pharmaceutical and biotech sponsors.
• Market Access & Payer Engagement Market access and payer engagement consulting that strategically positions pharmaceutical products to achieve optimal market access and payer alignment.
• Commercialization Strategy Strategic commercialization consulting that turns ideas into impact across the product lifecycle for pharmaceutical and biotech companies.
• Clinical & Regulatory Services Clinical and regulatory consulting that helps clients achieve timely product approvals and maximize market potential through regulatory expertise.
• Medical Affairs Strategy Medical affairs consulting that unlocks critical insights to elevate medical affairs strategy and engagement for pharmaceutical and biotech clients.

Quantifiable outcome

• Double-digit prescription growth for AVEO Oncology FOTIVDA campaign
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Evidera: A dedicated HEOR, market access, and real-world evidence consultancy (now part of Thermo Fisher Scientific via PPD). Most directly comparable to BresMed given its HEOR specialization serving global pharma and biotech.
• RTI Health Solutions: Independent HEOR and patient-centered outcomes consultancy serving pharma, biotech, and device clients. Directly comparable to BresMed in scope (HEOR, RWE, market access) and client base.
• Trinity Life Sciences: Life sciences strategy and HEOR-focused consultancy serving top pharma and biotech. Comparable to BresMed in commercial strategy, evidence generation, and value-demonstration offerings.
• Charles River Associates (CRA): Economic and strategy consultancy with a Life Sciences practice covering HEOR, pricing, and market access. Direct peer to BresMed on health economics and value-based pricing engagements.

Broad incumbents

• ICON plc: Global CRO with significant outcomes research and commercialization capabilities post-PRA Health Sciences. Competes with BresMed for HEOR and evidence-generation mandates within full-service clinical engagements.
• Parexel International: Global CRO with HEOR, market access, and real-world evidence services. Competes with BresMed on integrated evidence generation and value-demonstration engagements, particularly with large pharma.
• IQVIA: Largest life sciences services and data platform, with deep HEOR and real-world evidence capabilities. Direct competitor to BresMed at the enterprise tier via bundled evidence-and-data offerings.
• ZS Associates: Global management consulting firm with a large pharma and biotech practice spanning evidence, market access, and commercialization. Competes with BresMed on value-demonstration and launch strategy engagements.
• McKinsey & Company (Pharma & Medical Products): Top-tier management consultancy with a global pharma practice covering HEOR, market access, and commercialization strategy. Competes with BresMed for high-end strategic evidence and access mandates.

Emerging players

• Axtria: Data analytics and commercialization services firm for life sciences. Comparable to BresMed on evidence-generation and patient/HCP engagement analytics, particularly for biotech and specialty pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/lumanity
• LinkedInlinkedin.com/company/bresmed

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BresMed